Stay current with the latest press releases from within the industry.
London UK, 11 April 2012 - Based on its recent analysis of the responsive polymer for bio-medical application market, Frost & Sullivan recognises CIS Pharma with the 2011 European Frost & Sullivan... more
Innocoll Provides Update of Regulatory and Partnering Activities for CollaGUARD® Adhesion Barrier and Launches New Product Website more
Butyrylcholinesterase-targeted radiopharmaceuticals developed at the University of Nebraska Medical Center show promise for treatment of cancer. more
About Cerca Insights Cerca Insights core business is helping our customers to improve their drug discovery productivity. Cerca Insights is a Contract Research Organisation (CRO) based in Penang... more
euroPLX Introduces Tool to Overcome Reject vs. Accept Dilemma in Partnering
Genesis Conference on target to exceed all previous years
TDS® TESTOSTERONE EXCEEDS ANDROGEL® OUTCOMES
Labtec´s sufentanil patch for chronic pain enters phase II in cooperation with hameln rds GmbH
Alcon, the global leader in eye care and a division of Novartis, announced today that it has gained exclusive rights to commercialize ocriplasmin outside the United States for the treatment of symptomatic vitreomacular adhesion (VMA). If approved, it will (more)
euroPLX 48 Lisbon Schedules 4,000 Face-toFace Meetings
Partnering event productivity is measured by business negotiations per company, not by the total number of scheduled appointments. (more)
APR and Labtec announce to have received on February 8th, 2012, the marketing authorization through a decentralized procedure (DCP) in 15 European countries of Zolmitriptan ODF, a film strip formulation containing 2.5mg and 5mg Zolmitriptan . It is their (more)
Innocoll Announces Successful End-of-Phase 2 Meeting with FDA for XaraColl® and Agreement of the Phase 3 Program (more)
Innocoll Enters CollaGUARD® Distribution Partnership with Flynn Pharma Ltd in the UK and Inresa Arzneimittel GmbH in Germany (more)
APR Applied Pharma Research s.a. (“APR”), Labtec GmbH (“Labtec”) and Norgine BV (“Norgine”) announce the signature of an exclusive licensing agreement under which Norgine will market and distribute Setofilm™ Ondansetron Oral Dispersible Film (“ODF”), in E (more)
Norgine and APR, together with its joint venture partner Labtec, today announced that they have entered into an exclusive licensing agreement under which Norgine has acquired the commercialization rights in Europe and selected non-European countries in Mi (more)
The Most Important Business Platform for Many Life Science Companies
Returning customers make euroPLX the most often attended partnering conference. (more)
Innovaro Announces Successful Sale of the Waycool Portfolio of Patents by CUI Global, Inc.
Tampa, FL -- (Business Wire) – January 5, 2012 – Innovaro, Inc (NYSE Amex: INV), a leading IP licensing and innovation services company, is pleased to announce that its client CUI Global, Inc. (formerly Waytronx) has completed the sale of selected patents (more)
Signal Genetics to launch second generation Myeloma product, MyPRS Plus (more)